Skip to main content

Versameb raises 6 million Swiss francs

| News

Versameb raises 6 million Swiss francs

17.07.2020

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Using revenues obtained from a seed financing round totaling 6 million Swiss francs, Versameb is planning to bring its VERSagile platform to the clinical development stage by the end of 2021, as detailed in a press release. Versameb has developed VERSagile in order to program mRNA sequences for improved therapeutic efficacy. To this end, a molecular algorithm developed by the Basel-based company is used. The molecules developed in this fashion are designed to be used in the areas of dermatology and oncology, as well in the field of myology, the study of muscle diseases.

The potential of the Versameb approach was recognized very early on by the investment and innovation promotion agency Basel Area Business & Innovation, which supported the company in 2017/18 by way of BaseLaunch, the organization’s biotech accelerator and incubator. Versameb has now set its sights on driving forward the development of the company. To this end, it has strengthened its management team with the addition of Klaas P. Zuideveld, who has been appointed Chief Development Officer (CDO). He will bring a “rare combination” of scientific excellence and management experience to the role, according to Friedrich Metzger, Co-Founder and CEO of Versameb, who was quoted in the press release.

With Versameb having already achieved important milestones with the VERSagile platform, Dr. Reinhard Ambros, Chairman of the Board of Versameb and former Head of the Novartis Venture Fund, is delighted to see “that the company is attracting excellent talent to perform on our strategic and operational goals and that it is enjoying strong support from its investors”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.